10-Q: Nortech Systems Q3 Loss Narrows, Refinancing Debt Looms

Nortech Systems reported a reduced net loss in Q3 2025, driven by improved gross margins and operational efficiencies, despite a year-to-date decline in sales and an ongoing debt refinancing effort.

Summary

• Net sales for the three months ended September 30, 2025, decreased by 2.9% to $30,482 thousand from $31,407 thousand in the prior year.
• Net sales for the nine months ended September 30, 2025, decreased by 11.5% to $88,052 thousand from $99,513 thousand in the prior year.
• Gross profit for the three months ended September 30, 2025, increased by 31.0% to $5,025 thousand, with gross margin improving to 16.5% from 12.2%.
• Gross profit for the nine months ended September 30, 2025, decreased by 6.9% to $12,940 thousand, with gross margin improving to 14.7% from 14.0%.
• Operating income for the three months ended September 30, 2025, was $945 thousand, a significant improvement from an operating loss of $(467) thousand in the prior year.
• Operating income for the nine months ended September 30, 2025, was $74 thousand, a decrease from $1,032 thousand in the prior year.
• Net loss for the three months ended September 30, 2025, was $(146) thousand, a reduction from a net loss of $(739) thousand in the prior year.
• Net loss for the nine months ended September 30, 2025, was $(1,149) thousand, a shift from net income of $183 thousand in the prior year.
• Basic net loss per common share for Q3 2025 was $(0.05), compared to $(0.27) in Q3 2024.
• Basic net loss per common share for YTD 2025 was $(0.41), compared to net income per share of $0.07 in YTD 2024.
• Cash balance increased to $1,271 thousand as of September 30, 2025, from $916 thousand as of December 31, 2024.
• The 90-day shipment backlog increased by 5.7% year-over-year to $31,322 thousand, and total order backlog increased by 10.8% to $77,292 thousand.
• The company sold its Blue Earth manufacturing facility in July 2025 for $500 thousand, which approximated book value.
• Restructuring charges of $266 thousand were incurred in the nine months ended September 30, 2025, primarily for staff reductions and Blue Earth facility closure activities, with no charges in Q3 2025.
• The company's Revolving Line of Credit, with $12,030 thousand outstanding, matures on August 31, 2026, raising substantial doubt about its ability to continue as a going concern, though management believes refinancing is probable.

Sentiment

Score: 4

Explanation: While Q3 showed some operational improvements and a narrowed net loss, the year-to-date performance is significantly negative, with substantial declines in sales and a shift to a net loss. The 'going concern' warning, despite management's confidence in refinancing, introduces significant uncertainty and risk, outweighing the quarterly operational improvements. The overall financial health remains challenged.

Positives

• Net loss significantly narrowed in the third quarter of 2025 to $(146) thousand from $(739) thousand in the prior year.
• Gross profit margin improved substantially in Q3 2025 to 16.5% (up 430 basis points) and for the nine months ended September 30, 2025, to 14.7% (up 70 basis points), driven by improved plant utilization and favorable sales mix.
• Operating income for Q3 2025 was $945 thousand, a strong turnaround from an operating loss of $(467) thousand in Q3 2024.
• Cash balance increased to $1,271 thousand as of September 30, 2025, from $916 thousand at the end of 2024.
• The 90-day shipment backlog increased by 5.7% year-over-year to $31,322 thousand, and total order backlog increased by 10.8% to $77,292 thousand, primarily due to an increase in Aerospace and Defense orders.
• Medical Imaging net sales increased by 8.7% in Q3 2025 and 4.2% year-to-date, driven by higher sales volume to existing customers and new program awards.
• Management successfully secured waivers and amendments for its credit facility, demonstrating lender support despite covenant non-compliance.
• The company was in compliance with financial covenants related to adjusted EBITDA for the third quarter of 2025.

Negatives

• Net sales decreased by 2.9% in Q3 2025 and 11.5% year-to-date, primarily due to delays in Aerospace and Defense customer approvals, manufacturing inefficiencies, customer order delays, and part shortages.
• The company reported a net loss of $(1,149) thousand for the nine months ended September 30, 2025, a significant decline from net income of $183 thousand in the prior year.
• Operating income for the nine months ended September 30, 2025, decreased significantly to $74 thousand from $1,032 thousand in the prior year, driven by lower net sales.
• Interest expense increased by 26.4% in Q3 2025 and 35.8% year-to-date due to higher borrowings under the line of credit.
• The company's Revolver, with $12,030 thousand outstanding, matures on August 31, 2026, and the uncompleted refinancing plan raises substantial doubt about its ability to continue as a going concern.
• Aerospace and Defense net sales decreased significantly by 28.3% in Q3 2025 and 34.2% year-to-date, mainly due to customer approval delays and production transfers.
• Medical Device net sales decreased by 1.6% in Q3 2025 and 9.5% year-to-date, attributed to inventory re-balancing, timing of product launches, and lower productivity from facility consolidation.
• Industrial net sales decreased by 2.6% in Q3 2025 and 14.4% year-to-date due to customer order delays and part shortages.
• The effective tax rate was highly volatile, at 122% for Q3 2025 and (71)% for YTD 2025, impacted by pretax income/loss fluctuations, foreign entity taxes, and GILTI provisions.

Risks

• Failure to comply with credit agreement covenants could lead to an inability to secure additional financing and acceleration of repayment obligations on outstanding indebtedness.
• Impairment of long-lived assets, particularly if fair value declines below carrying value, could result in material non-cash impairment charges, negatively impacting results and debt covenant compliance.
• Volatility in the marketplace may affect market supply, demand for products, or currency exchange rates.
• Supply chain disruptions and unreliability could impact production and delivery schedules.
• Lack of sufficient human resources to produce products could hinder operational capacity.
• Increased competition within the EMS industry or decisions by OEMs to cease or limit outsourcing could reduce market share and revenue.
• Changes in the reliability and efficiency of operating facilities or those of third parties could disrupt operations.
• Increases in certain raw material costs (e.g., copper, oil) and commodity/energy cost instability could impact profitability.
• Risks related to FDA noncompliance could lead to regulatory penalties or product recalls.
• The loss of a major customer could significantly impact net sales and financial performance.
• General economic, financial, and business conditions could adversely affect financial condition and results of operations.
• Increased or unanticipated costs related to compliance with securities and environmental regulations.
• Disruption of global or local information management systems due to natural disaster or cyber-security incidents.
• Outbreaks of epidemic, pandemic, or contagious diseases could affect operations, customer operations, or supplier operations.

Future Outlook

Management believes it will have sufficient liquidity for the next twelve months based on planned refinancing, anticipated operating cash flows, and cash on hand. The company is executing a plan to refinance its maturing cash-flow-based Revolver to an asset-backed line of credit and has received non-binding term sheets from multiple lenders. They expect to realize reduced borrowings during the fourth quarter of 2025 due to plant optimization, cost-cutting initiatives, and continued efforts to improve manufacturing efficiencies and reduce inventory levels.

Management Comments

• "Over the past two quarters, we have improved our manufacturing efficiencies as we complete product transfers between plants and realize improved manufacturing yields and productivity."
• "Based on the planned refinancing arrangement, anticipated operating cash flows, and cash on hand, we believe we will have sufficient liquidity to satisfy our working capital needs, capital expenditures and debt repayments for the next twelve months."
• "Management believes it is probable that the refinancing will be effectively implemented before the maturity of the Revolver and will mitigate the conditions that raise substantial doubt [about going concern]."
• "The Company implemented plant optimization activities and cost-cutting initiatives in the first two quarters of 2025 to address losses. As a result of these activities, we have realized combined income from operations of $1,687 over the past two quarters."
• "These actions plus continued efforts to improve manufacturing efficiencies and the planned reduction in inventory levels are intended to drive reduced borrowings during the fourth quarter of 2025."

Industry Context

The company operates in the Electronic Manufacturing Services (EMS) industry, serving Medical Device, Medical Imaging, Aerospace and Defense, and Industrial markets. The overall decline in net sales, particularly in Aerospace and Defense and Industrial sectors, suggests potential headwinds in these segments, possibly due to broader economic slowdowns, supply chain issues, or customer-specific delays. The growth in Medical Imaging, however, indicates resilience or specific market opportunities within that sector. The focus on lean manufacturing and global footprint expansion aligns with industry trends towards efficiency and diversified supply chains.

Comparison to Industry Standards

• The company's gross margin improvement to 16.5% in Q3 2025 is a positive sign, but without specific industry benchmarks for comparable EMS providers in its niche markets (Medical Device, Aerospace & Defense), it's difficult to definitively assess against global standards. However, the improvement itself suggests better operational execution relative to its own past performance.
• The significant decline in Aerospace and Defense sales (34.2% YTD) contrasts with a generally robust defense spending environment, suggesting company-specific issues like customer approval delays and facility transfers rather than broad industry weakness. Competitors like Benchmark Electronics or Plexus Corp. might show different trends in their defense segments.
• The company's reliance on a few major customers (Customer A representing 31% of YTD sales, Customer B 10%) is common in contract manufacturing but can pose a concentration risk compared to more diversified industry players.
• The 'going concern' warning, even with management's confidence in refinancing, places the company below the financial stability standards of well-capitalized industry peers, who typically maintain stronger liquidity and less reliance on short-term debt refinancing.

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings and claims that arise in the ordinary course of business.

Related Party Transactions

• David Kunin, Chairman, was a minority owner of Abilitech Medical, Inc. Accounts receivable of $226 thousand related to Abilitech were written off in 2024 as Abilitech ceased operations.
• David Kunin, Chairman, is a minority owner (less than 10%) and Board member of Marpe Technologies, LTD, an early-stage medical device company.
• The company and Marpe Technologies received approval for a $1,000 thousand conditional grant from the BIRD Foundation, with each party receiving $500 thousand and contributing $500 thousand in matching funds/services.
• The company's contribution to Marpe Technologies involved providing certain services at cost or administrative services at no cost, not exceeding $500 thousand.
• The company will receive a 10-year exclusive right to manufacture the products of Marpe Technologies.
• Net sales to Marpe Technologies were $0 in Q3/YTD 2025, compared to $8 thousand in Q3 2024 and $75 thousand in YTD 2024.
• As of September 30, 2025, there are no outstanding accounts receivable from Marpe Technologies.
• Transactions with Abilitech and Marpe are believed to be on terms comparable to arms-length transactions.

Stakeholder Impact

• **Shareholders**: Face significant uncertainty due to the 'going concern' warning and the need for debt refinancing. The year-to-date net loss and declining sales could negatively impact share value, despite Q3 operational improvements. Potential dilution from future capital raises is a risk.
• **Creditors (Bank of America)**: Have shown flexibility through multiple amendments to the Revolver, but the company's ability to meet future covenants and successfully refinance remains critical for debt repayment.
• **Employees**: Affected by workforce reductions in Q1 2025 as part of restructuring activities. Continued operational efficiencies and cost-cutting could lead to further impacts.
• **Customers**: Experienced delays in product approvals (Aerospace and Defense) and order delays/part shortages (Industrial), which could impact customer satisfaction and future orders. The company's focus on quality and on-time delivery is crucial for retaining customer trust.
• **Suppliers**: May face pressure on payment terms or reduced order volumes if the company's financial health does not stabilize or if supply chain issues persist.

Next Steps

• Refinance the maturing cash-flow-based Revolver to an asset-backed line of credit before its August 31, 2026, maturity.
• Continue plant optimization activities and cost-cutting initiatives to improve manufacturing efficiencies and reduce inventory levels.
• Maintain adjusted EBITDA of at least $1,600 thousand for Q4 2025 and each quarter thereafter, as per credit agreement covenants.
• Maintain a leverage ratio of no more than 2.5 times for the year ended December 31, 2025, and thereafter.
• Maintain a minimum fixed charge coverage ratio of at least 1.25 times for the year ended December 31, 2025, and thereafter.
• Maintain Liquidity (unrestricted cash and Revolver availability) of at least $2,500 thousand.
• Review the impact of the One Big Beautiful Bill Act (OBBBA) and various tax elections to optimize tax cash payments and overall tax expense.

Key Dates

Recommendation

While Nortech Systems showed a notable improvement in Q3 2025 operating income and a narrowed net loss, the year-to-date performance remains weak with significant revenue declines and a substantial net loss. The explicit 'going concern' warning, despite management's confidence in refinancing, introduces a high level of financial risk and uncertainty. The increase in backlog is a positive signal for future revenue, and gross margin improvements indicate better operational efficiency. However, the company's ability to successfully execute its refinancing plan and return to sustained profitability is paramount. Given the mixed signals – operational improvements in the quarter versus significant year-to-date losses and critical liquidity concerns – a 'hold' recommendation is appropriate. Investors should monitor the refinancing progress and future financial results closely before making further investment decisions.

Keywords

Contract Manufacturing, EMS, Medical Device, Medical Imaging, Aerospace and Defense, Industrial, SEC Filing, 10-Q, Financial Results, Quarterly Report, Revenue, Profitability, Backlog, Debt Refinancing, Going Concern, Credit Covenants, Restructuring, Supply Chain, Operational Efficiency